JP2014511866A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014511866A5 JP2014511866A5 JP2014504086A JP2014504086A JP2014511866A5 JP 2014511866 A5 JP2014511866 A5 JP 2014511866A5 JP 2014504086 A JP2014504086 A JP 2014504086A JP 2014504086 A JP2014504086 A JP 2014504086A JP 2014511866 A5 JP2014511866 A5 JP 2014511866A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- chimeric polypeptide
- fragment
- par2
- mutation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 51
- 229920001184 polypeptide Polymers 0.000 claims 41
- 102000004196 processed proteins & peptides Human genes 0.000 claims 41
- 102000032628 PAR-2 Receptor Human genes 0.000 claims 22
- 108010070503 PAR-2 Receptor Proteins 0.000 claims 22
- 239000012634 fragment Substances 0.000 claims 22
- 230000035772 mutation Effects 0.000 claims 19
- 102000002020 Protease-activated receptors Human genes 0.000 claims 18
- 108050009310 Protease-activated receptors Proteins 0.000 claims 18
- 150000001413 amino acids Chemical class 0.000 claims 14
- 125000000539 amino acid group Chemical group 0.000 claims 10
- 108010070519 PAR-1 Receptor Proteins 0.000 claims 8
- 102100037136 Proteinase-activated receptor 1 Human genes 0.000 claims 8
- 230000002209 hydrophobic effect Effects 0.000 claims 8
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims 7
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims 7
- 230000003834 intracellular effect Effects 0.000 claims 7
- 238000006467 substitution reaction Methods 0.000 claims 4
- 230000037430 deletion Effects 0.000 claims 3
- 238000012217 deletion Methods 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 101001086405 Bos taurus Rhodopsin Proteins 0.000 claims 2
- 150000008574 D-amino acids Chemical class 0.000 claims 2
- 101000613565 Homo sapiens PRKC apoptosis WT1 regulator protein Proteins 0.000 claims 2
- 101001135199 Homo sapiens Partitioning defective 3 homolog Proteins 0.000 claims 2
- 101001098557 Homo sapiens Proteinase-activated receptor 3 Proteins 0.000 claims 2
- 101001113471 Homo sapiens Proteinase-activated receptor 4 Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102100037133 Proteinase-activated receptor 3 Human genes 0.000 claims 2
- 102100023710 Proteinase-activated receptor 4 Human genes 0.000 claims 2
- 208000003251 Pruritus Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000816 peptidomimetic Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 1
- 206010051113 Arterial restenosis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 101001098560 Homo sapiens Proteinase-activated receptor 2 Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010022998 Irritability Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000035268 Mast Cell Activation disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 150000003855 acyl compounds Chemical class 0.000 claims 1
- 238000007792 addition Methods 0.000 claims 1
- 230000001270 agonistic effect Effects 0.000 claims 1
- 230000003042 antagnostic effect Effects 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000000170 cell membrane Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 210000004392 genitalia Anatomy 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 102000050100 human F2RL1 Human genes 0.000 claims 1
- 206010021198 ichthyosis Diseases 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000004941 influx Effects 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 230000007803 itching Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 125000003588 lysine group Chemical class [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 208000008585 mastocytosis Diseases 0.000 claims 1
- 210000002752 melanocyte Anatomy 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 125000001360 methionine group Chemical class N[C@@H](CCSC)C(=O)* 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 210000004994 reproductive system Anatomy 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161473675P | 2011-04-08 | 2011-04-08 | |
| US61/473,675 | 2011-04-08 | ||
| PCT/US2012/032824 WO2012139137A2 (en) | 2011-04-08 | 2012-04-09 | Pepducin design and use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014511866A JP2014511866A (ja) | 2014-05-19 |
| JP2014511866A5 true JP2014511866A5 (https=) | 2015-05-28 |
| JP6225104B2 JP6225104B2 (ja) | 2017-11-01 |
Family
ID=46969875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014504086A Expired - Fee Related JP6225104B2 (ja) | 2011-04-08 | 2012-04-09 | ペプデューシンの設計および使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10913781B2 (https=) |
| EP (2) | EP3351641A1 (https=) |
| JP (1) | JP6225104B2 (https=) |
| AU (1) | AU2012239880B2 (https=) |
| CA (1) | CA2832115C (https=) |
| WO (1) | WO2012139137A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3351641A1 (en) | 2011-04-08 | 2018-07-25 | Tufts Medical Center, Inc. | Pepducin design and use |
| SG10201708125PA (en) | 2013-04-05 | 2017-11-29 | Biomarck Pharmaceuticals Ltd | Inhibitors of metastasis |
| HK1223096A1 (zh) | 2013-09-25 | 2017-07-21 | Vertex Pharmaceuticals Incorporated | 用作par-2信號通路抑制劑的咪唑並噠嗪 |
| WO2017083618A1 (en) | 2015-11-13 | 2017-05-18 | Oasis Pharmaceuticals, LLC | Protease-activated receptor-2 modulators |
| WO2017194716A1 (en) * | 2016-05-12 | 2017-11-16 | Astrazeneca Ab | Inhibitors of protease-activated receptor-2 |
| WO2020201572A1 (en) | 2019-04-05 | 2020-10-08 | Université De Bretagne Occidentale | Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning |
| KR102268589B1 (ko) * | 2019-04-29 | 2021-06-24 | 사회복지법인 삼성생명공익재단 | 단백질분해효소 활성 수용체 매개 신호전달 경로의 활성을 이용한 세포외 소포의 고효율 생성능을 갖는 줄기세포의 선별방법 |
| EP4595983A1 (en) * | 2024-02-05 | 2025-08-06 | BXTA Nanotherapy Limited | Nanoparticles functionalised with a stabilising agent and a targeting agent |
| WO2025172573A1 (en) | 2024-02-16 | 2025-08-21 | Domain Therapeutics | Combinations of par2 inhibitors and immune checkpoint inhibitors for the treatment of cancer |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9266930B1 (en) | 1993-03-05 | 2016-02-23 | Epimmune Inc. | Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions |
| EP0835928A1 (en) | 1996-10-11 | 1998-04-15 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin | Helicobacter pylori live vaccine |
| US7368531B2 (en) | 1997-03-07 | 2008-05-06 | Human Genome Sciences, Inc. | Human secreted proteins |
| US6747137B1 (en) | 1998-02-13 | 2004-06-08 | Genome Therapeutics Corporation | Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics |
| US6815200B1 (en) | 1998-02-17 | 2004-11-09 | The Uab Research Foundation | Modified adenovirus containing a fiber replacement protein |
| DE69942176D1 (de) | 1998-04-07 | 2010-05-06 | Medimmune Llc | Choline-bindende proteine derivate aus pneumokoken als impfstoff |
| US6562958B1 (en) | 1998-06-09 | 2003-05-13 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Acinetobacter baumannii for diagnostics and therapeutics |
| US6228989B1 (en) * | 1998-11-13 | 2001-05-08 | The Regents Of The University Of California | Peptide substrates phosphorylated by P21-activated protein kinase |
| WO2000034469A1 (en) | 1998-12-11 | 2000-06-15 | The Research Foundation Of State University Of New York At Albany | Compositions and methods for altering cell migration |
| US6703491B1 (en) | 1999-03-17 | 2004-03-09 | Exelixis, Inc. | Drosophila sequences |
| US20040002068A1 (en) | 2000-03-01 | 2004-01-01 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| EP2348047A1 (en) | 2000-04-21 | 2011-07-27 | New England Medical Center | G protein coupled receptor (GPCR) agonists and antagonists and methods of activating and inhibiting GPCR using the same |
| US7696168B2 (en) | 2000-04-21 | 2010-04-13 | Tufts Medical Center, Inc. | G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same |
| US6773893B1 (en) | 2000-04-28 | 2004-08-10 | The Trustees Of Columbia University In The City Of New York | Human ABC1 promoter and assays based thereon |
| US7834146B2 (en) | 2000-05-08 | 2010-11-16 | Monsanto Technology Llc | Recombinant polypeptides associated with plants |
| EP1197755A1 (en) | 2000-10-11 | 2002-04-17 | Pepscan Systems B.V. | Identification of protein binding sites |
| US7214786B2 (en) | 2000-12-14 | 2007-05-08 | Kovalic David K | Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement |
| SE0201863D0 (en) | 2002-06-18 | 2002-06-18 | Cepep Ab | Cell penetrating peptides |
| CA2492938C (en) | 2002-08-02 | 2012-05-22 | Joseph H. Coggin, Jr. | Cancer vaccines containing epitopes of oncofetal antigen |
| US7683031B2 (en) | 2002-09-03 | 2010-03-23 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Short peptides from the ‘2nd loop’ of 7 transmembrane receptor which selectively modulate signal transduction |
| DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| WO2004067712A2 (en) * | 2003-01-22 | 2004-08-12 | Incyte Corporation | Intracellular signaling molecules |
| US7189691B2 (en) | 2004-04-01 | 2007-03-13 | The Administrators Of The Tulane Educational Fund | Methods and compositions for treating leukemia |
| US20070207209A1 (en) | 2004-08-27 | 2007-09-06 | Murphy Christopher J | Trophic factor combinations for nervous system treatment |
| US7319142B1 (en) | 2004-08-31 | 2008-01-15 | Monsanto Technology Llc | Nucleotide and amino acid sequences from Xenorhabdus and uses thereof |
| JP2008519039A (ja) | 2004-11-04 | 2008-06-05 | ニュー イングランド メデカル センター ホスピタルズ インク | Ｇタンパク質共役型受容体アゴニストおよびアンタゴニストならびに使用方法 |
| US8088976B2 (en) | 2005-02-24 | 2012-01-03 | Monsanto Technology Llc | Methods for genetic control of plant pest infestation and compositions thereof |
| WO2007061850A2 (en) | 2005-11-17 | 2007-05-31 | Massachusetts Institute Of Technology | Methods and systems for generating and evaluating peptides |
| US8575070B2 (en) | 2006-02-20 | 2013-11-05 | Phylogica Limited | Methods of constructing and screening libraries of peptide structures |
| AU2007284651B2 (en) | 2006-08-09 | 2014-03-20 | Institute For Systems Biology | Organ-specific proteins and methods of their use |
| TW201531484A (zh) | 2007-05-21 | 2015-08-16 | Alder Biopharmaceuticals Inc | 抗ＴＮＦ-α之抗體及其用途 |
| JP4400668B2 (ja) | 2007-11-01 | 2010-01-20 | 株式会社豊田中央研究所 | 微小物体が固定化された固相体の製造方法及びその利用 |
| US9029636B2 (en) | 2008-02-05 | 2015-05-12 | Monsanto Technology Llc | Isolated novel nucleic acid and protein molecules from soy and methods of using those molecules to generate transgenic plants with enhanced agronomic traits |
| WO2010053545A2 (en) | 2008-11-04 | 2010-05-14 | Anchor Therapeutics, Inc. | Apj receptor compounds |
| JP2012507524A (ja) | 2008-11-04 | 2012-03-29 | アンカー セラピューティクス，インコーポレイテッド | Ｃｘｃｒ４受容体化合物 |
| US20100184684A1 (en) | 2009-01-06 | 2010-07-22 | C3 Jian, Inc. | Antibacterial and antifungal peptides |
| US9012723B2 (en) | 2009-01-16 | 2015-04-21 | Monsanto Technology Llc | Isolated novel acid and protein molecules from soy and methods of using those molecules to generate transgene plants with enhanced agronomic traits |
| WO2010091294A2 (en) | 2009-02-05 | 2010-08-12 | The Regents Of The University Of California | New targeted antimicrobial moieties |
| US20120121706A1 (en) * | 2009-04-10 | 2012-05-17 | Tufts Medical Center, Inc. | PAR-1 Activation by Metalloproteinase-1 (MMP-1) |
| US8501930B2 (en) | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
| EP3351641A1 (en) | 2011-04-08 | 2018-07-25 | Tufts Medical Center, Inc. | Pepducin design and use |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
-
2012
- 2012-04-09 EP EP17199261.3A patent/EP3351641A1/en not_active Withdrawn
- 2012-04-09 WO PCT/US2012/032824 patent/WO2012139137A2/en not_active Ceased
- 2012-04-09 EP EP12767963.7A patent/EP2697386B1/en not_active Not-in-force
- 2012-04-09 CA CA2832115A patent/CA2832115C/en not_active Expired - Fee Related
- 2012-04-09 US US14/009,479 patent/US10913781B2/en active Active
- 2012-04-09 JP JP2014504086A patent/JP6225104B2/ja not_active Expired - Fee Related
- 2012-04-09 AU AU2012239880A patent/AU2012239880B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014511866A5 (https=) | ||
| AU2010202328B2 (en) | G Protein Coupled Receptor Agonists and Antagonists and Methods of Use | |
| US9969787B2 (en) | Glucagon-like-peptide-2 (GLP-2) analogues | |
| JP2014524908A5 (https=) | ||
| US10092648B2 (en) | Selective glucagon-like-peptide-2 (GLP-2) analogues | |
| JP2014525901A5 (https=) | ||
| ES2984663T3 (es) | Moduladores del receptor 2 activados por proteasa | |
| HRP20201353T1 (hr) | Agonisti glukagonskog receptora | |
| HRP20170890T1 (hr) | Suagonisti glukagonskog/glp-1 receptora | |
| BR112015010203B1 (pt) | uso de uma composição para a preparação de um medicamento para a prevenção ou o tratamento de diabetes, complicações diabéticas ou diabesidade compreendendo um conjugado analogo da oxintomodulina | |
| BR112015001596B1 (pt) | Uso de uma composição compreendendo um derivado de oxintomodulina como um ingrediente ativo e uso de um derivado de oxintomodulina | |
| JP2011526303A5 (https=) | ||
| JP2011518179A5 (https=) | ||
| US9731007B2 (en) | Tumour necrosis factor receptor fusion proteins and methods of using the same | |
| JP2018537529A5 (https=) | ||
| EP4337681A1 (en) | Therapeutic derivatives of interleukin-22 | |
| JP2013535965A5 (https=) | ||
| ES2575517T3 (es) | Péptidos de unión a FGF2 y usos de los mismos |